TAK 925

Drug Profile

TAK 925

Alternative Names: TAK-925

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Sleep disorder therapies
  • Mechanism of Action Orexin-receptor-type-2-agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Narcolepsy

Most Recent Events

  • 16 May 2018 Phase-I clinical trials in Narcolepsy (In volunteers) in USA (IV) (NCT03522506)
  • 04 May 2018 Takeda plans a phase I trial for Sleep-deprived healthy volunteers in May 2018 , (NCT03522506)
  • 19 Dec 2017 TAK 925 receives Orphan Drug status for Narcolepsy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top